Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Zachary Scott Wallace, M.D.

Co-Author

This page shows the publications co-authored by Zachary Wallace and Jeffrey Sparks.
Connection Strength

4.077
  1. Clinical characteristics and outcomes of COVID-19 breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases. Ann Rheum Dis. 2021 Sep 06.
    View in: PubMed
    Score: 0.246
  2. Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. RMD Open. 2021 09; 7(3).
    View in: PubMed
    Score: 0.245
  3. Coronavirus disease 2019: update on coronavirus disease 2019 outcomes and vaccine efficacy in patients with immune-mediated inflammatory disease. Curr Opin Rheumatol. 2021 09 01; 33(5):412-418.
    View in: PubMed
    Score: 0.245
  4. Response to: Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis" by Sparks et al. Ann Rheum Dis. 2021 Aug 23.
    View in: PubMed
    Score: 0.245
  5. Response to: Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis" by Sparks et al. Ann Rheum Dis. 2021 Aug 13.
    View in: PubMed
    Score: 0.245
  6. Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. Ann Rheum Dis. 2021 09; 80(9):1137-1146.
    View in: PubMed
    Score: 0.241
  7. Laboratory trends, hyperinflammation, and clinical outcomes for patients with a systemic rheumatic disease admitted to hospital for COVID-19: a retrospective, comparative cohort study. Lancet Rheumatol. 2021 Sep; 3(9):e638-e647.
    View in: PubMed
    Score: 0.241
  8. Incident systemic rheumatic disease following COVID-19. Lancet Rheumatol. 2021 Jun; 3(6):e402-e404.
    View in: PubMed
    Score: 0.239
  9. Response to: 'Correspondence on 'SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease'' by Shanoj et al. Ann Rheum Dis. 2021 Mar 10.
    View in: PubMed
    Score: 0.237
  10. SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease. Ann Rheum Dis. 2021 Jan 12.
    View in: PubMed
    Score: 0.235
  11. Coronavirus disease 2019 outcomes among patients with rheumatic diseases 6 months into the pandemic. Ann Rheum Dis. 2021 05; 80(5):660-666.
    View in: PubMed
    Score: 0.233
  12. Response to: 'COVID-19 in patients with rheumatic diseases: what is the real mortality risk?' by Marques et al. Ann Rheum Dis. 2020 Jul 13.
    View in: PubMed
    Score: 0.227
  13. Response to: 'Incidence of severe COVID-19 in a Spanish cohort of 1037 patients with rheumatic diseases treated with biologics and JAK-inhibitors' by Jovani et al. Ann Rheum Dis. 2020 Jun 25.
    View in: PubMed
    Score: 0.226
  14. Response to: 'COVID-19 in patients with rheumatological diseases treated with Anti-TNF' by Brito et al and 'Clinical characteristics and outcomes of patients with COVID-19 and rheumatic disease in China 'hot spot' versus in US 'hot spot': similarities and differences' by Zhao et al. Ann Rheum Dis. 2021 05; 80(5):e64.
    View in: PubMed
    Score: 0.226
  15. Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US 'hot spot'. Ann Rheum Dis. 2020 09; 79(9):1156-1162.
    View in: PubMed
    Score: 0.225
  16. Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19. JAMA Netw Open. 2021 10 01; 4(10):e2129639.
    View in: PubMed
    Score: 0.062
  17. COVID-19 in Pregnant Women With Rheumatic Disease: Data From the COVID-19 Global Rheumatology Alliance. J Rheumatol. 2021 Sep 01.
    View in: PubMed
    Score: 0.061
  18. Immediate effect of the COVID-19 pandemic on patient health, health-care use, and behaviours: results from an international survey of people with rheumatic diseases. Lancet Rheumatol. 2021 Oct; 3(10):e707-e714.
    View in: PubMed
    Score: 0.061
  19. Association of Race and Ethnicity With COVID-19 Outcomes in Rheumatic Disease: Data From the COVID-19 Global Rheumatology Alliance Physician Registry. Arthritis Rheumatol. 2021 03; 73(3):374-380.
    View in: PubMed
    Score: 0.059
  20. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2021 07; 80(7):930-942.
    View in: PubMed
    Score: 0.059
  21. Antirheumatic Disease Therapies for the Treatment of COVID-19: A Systematic Review and Meta-Analysis. Arthritis Rheumatol. 2021 01; 73(1):36-47.
    View in: PubMed
    Score: 0.058
  22. Acute respiratory viral adverse events during use of antirheumatic disease therapies: A scoping review. Semin Arthritis Rheum. 2020 10; 50(5):1191-1201.
    View in: PubMed
    Score: 0.057
  23. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020 07; 79(7):859-866.
    View in: PubMed
    Score: 0.056
  24. Barriers and Facilitators of Mentoring for Trainees and Early Career Investigators in Rheumatology Research: Current State, Identification of Needs, and Road Map to an Inter-Institutional Adult Rheumatology Mentoring Program. Arthritis Care Res (Hoboken). 2018 03; 70(3):445-453.
    View in: PubMed
    Score: 0.048
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.